Clinical Scorecard: Fundamentals of PET Molecular Imaging in Dementia and Parkinsonism-Related Neurodegenerative Disorders
At a Glance
Category
Detail
Condition
Neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia, primary progressive aphasia, progressive supranuclear palsy, and dementia with Lewy bodies
Key Mechanisms
Protein aggregation (amyloid-β plaques, tau neurofibrillary tangles), neuronal activity changes, and presynaptic dopaminergic dysfunction
Target Population
Adult patients with cognitive impairment and/or parkinsonism being evaluated for neurodegenerative disorders
Care Setting
Specialized clinical and research centers with PET imaging capabilities
Key Highlights
PET imaging biomarkers enable in vivo quantification of molecular targets, allowing earlier and more accurate diagnosis of neurodegenerative diseases.
Amyloid PET tracers detect amyloid-β plaques years before clinical symptoms of Alzheimer's disease appear, aiding early diagnosis and clinical trial recruitment.
FDG-PET measures glucose metabolism to detect characteristic hypometabolism patterns in various neurodegenerative diseases before structural MRI changes.
Guideline-Based Recommendations
Diagnosis
Use amyloid PET imaging to estimate amyloid-β plaques in adult patients with cognitive impairment suspected of Alzheimer's disease.
Employ FDG-PET to identify hypometabolism patterns characteristic of different neurodegenerative disorders.
Utilize tau PET imaging to visualize neurofibrillary tangles and track disease progression in Alzheimer's disease.
Management
Incorporate PET imaging results to confirm or exclude Alzheimer's disease diagnosis and guide patient management.
Use PET biomarkers to monitor response to anti-amyloid therapies and disease progression.
Monitoring & Follow-up
Perform follow-up amyloid PET scans to assess changes in amyloid deposition over time.
Use tau PET imaging to monitor neurodegeneration and disease progression more closely than amyloid imaging.
Risks
No contraindications have been described for amyloid PET imaging.
Be aware of potential pitfalls and artefacts in PET image acquisition and interpretation.
Patient & Prescribing Data
Adults with cognitive impairment or parkinsonism under evaluation for neurodegenerative diseases
PET imaging aids in early diagnosis, patient stratification for clinical trials, and monitoring therapeutic effects, particularly for disease-modifying treatments targeting amyloid and tau pathology.
Clinical Best Practices
Interpret PET images considering characteristic regional patterns of tracer uptake and hypometabolism specific to each neurodegenerative disorder.
Use fluorine-18 labelled amyloid PET tracers ([18F]florbetapir, [18F]florbetaben, [18F]flutemetamol) for wider clinical accessibility due to longer half-life and validated performance.
Recognize that amyloid PET tracers have high nonspecific white matter uptake which must be accounted for during image interpretation.
Combine PET imaging findings with clinical and other diagnostic data for comprehensive patient evaluation.
Ensure PET imaging is performed and interpreted by trained specialists familiar with neurodegenerative disease patterns and potential artefacts.
